Announcement
Newcastle University is seeking to recruit a new Clinical Chair in Molecular Pathology. This exciting opportunity will be advertised in September 2017. We will be looking for a talented and highly motivated individual to spearhead our programme in Molecular Pathology, working closely with the Newcastle EPSRC/MRC Molecular Pathology Node one of six awarded across the UK.
The Public and Patient Involvement team at Cancer Research UK has developed a new Patient and Public Involvement (PPI) in Research Toolkit for the research community. This toolkit is packed with resources, information, and guidance to support PPI in cancer research.
As part of the new quinquennium, Cardiff ECMC has begun setting up an ECMC Haematology network. The main purpose of this group is to promote haematology activities within the ECMC and consider ways it can work collectively as a group.
The ECMC Translational Science subgroup of QATS (Quality Assurance & Translational Science group) organised its very first conference titled ‘Opportunities and challenges with emerging biomarker technologies and their application in early phase trials’ on 20 March. The one-day event was held at the ICR in Sutton and organised by Karen Swales, Senior Scientific Officer, ICR CRUK Therapeutics Unit and chair of the Translational Science subgroup.
Both the CRUK Stratified Medicine Programme (SMP2) and the National Lung Matrix Trial (NLMT) are at a crucial phase of trial delivery.
SMP2 and NLMT are open to recruitment at 17 and 16 ECMCs respectively. Both study teams are collaborating to set up three new sites (Liverpool, Maidstone and Devon and Exeter) as part of a phased approach that aims to introduce several new sites across the country.
The development of new treatments for pancreatic cancer is set to be transformed by a £10m investment by Cancer Research UK into a network of clinical trials, aiming to find the right trial for the right patient.
The UK's only current trial dedicated to the treatment of myelomonocytic leukaemia (CMML) has recruited its first patient. The Phase II MONOCLE study has opened at the Institute of Cancer & Genetics at Cardiff University, and has received funding support from the Cardiff ECMC.
A Phase I-II study supported by UCL ECMC has found that rucaparib can be used in the treatment of patients with high-grade ovarian cancer.
Welsh patients are to be some of the first in the world to access the drug-radiation combination trial, known as PARADIGM 2. The trial co-funded by Cancer Research UK and The Brain Tumour Charity, and is part of CRUK's ECMC Combinations Alliance and will be run at Velindre Cancer Centre by Dr James Powell.
Cancer Research UK is running sandpit-style workshops to generate innovative projects in cancer research